Status:
RECRUITING
mtDNA Mutation Load Analysis in Mesoangioblasts
Lead Sponsor:
Maastricht University
Conditions:
Mitochondrial Myopathies
Eligibility:
All Genders
18+ years
Brief Summary
Mitochondrial diseases caused by defects in oxidative phosphorylation (OXPHOS) due to heteroplasmic mitochondrial DNA (mtDNA) mutations are rare (frequency 1/5,000), but severe multi-system disorders....
Detailed Description
Rationale: Mitochondrial diseases caused by defects in oxidative phosphorylation (OXPHOS) due to heteroplasmic mitochondrial DNA (mtDNA) mutations are rare (frequency 1/5,000), but severe multi-system...
Eligibility Criteria
Inclusion
- Inclusion Criteria all participants:
- Written informed consent
- Age: 18+
- Sex: male/female
- Carriers of a heteroplasmic mtDNA mutation load \>20% in skeletal muscle or \>1% in blood
- Exclusion Criteria all participants:
- No informed consent
- Use of anti-coagulants, anti-thrombotics and other medication influencing coagulation
- Have a weekly alcohol intake of ≥ 35 units (men) or ≥ 24 units (women)
- Current history of drug abuse
- A history of strokes
- Significant concurrent illness
- Ongoing participation in other clinical trials that contain an intervention
- Major surgery within 4 weeks of the visit
- Pregnant or lactating women
- Patients unable and/or unwilling to comply with treatment and study instructions
Exclusion
Key Trial Info
Start Date :
December 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05199740
Start Date
December 20 2022
End Date
July 1 2026
Last Update
January 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University
Maastricht, Netherlands